Gufic Biosciences Ltd Stock Price Today (NSE: GUFICBIO)
Fundamental Score
Gufic Biosciences Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Gufic Biosciences Ltd share price today is ₹291.80, up +0.00% on NSE/BSE as of 19 February 2026. Gufic Biosciences Ltd (GUFICBIO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.51K (Cr). The 52-week high for GUFICBIO share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 64.59x, GUFICBIO is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.32% and a debt-to-equity ratio of 0.59.
Gufic Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Gufic Biosciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Gufic Biosciences Share Price: A Conservative Value Investor's Perspective
The Indian pharmaceutical sector, while often seen as defensive due to its essential nature, is increasingly facing pricing pressures and regulatory scrutiny, making careful selection crucial for the value investor. This analysis examines the current valuation of Gufic Biosciences share price, focusing on key metrics relevant to capital preservation. We are conducting this analysis as part of a detailed 80-parameter fundamental audit, verified by Sweta Mishra, to ensure a comprehensive assessment.
At a price of ₹308.049988, Gufic Biosciences trades at a Price-to-Earnings (PE) ratio of 64.59. This is significantly higher than the sector average, suggesting a rich valuation. Comparing this to a peer like
Mankind Pharma Ltd, which commands premium valuations based on perceived management quality and brand strength, it is crucial to assess whether Gufic Biosciences' management team exhibits similar capabilities in efficient capital allocation and navigating the complex regulatory landscape. A high PE alone does not guarantee future returns and necessitates a deep dive into the underlying fundamentals.Return on Capital Employed (ROCE) is a critical metric for assessing a company's efficiency in generating profits from its capital. Gufic Biosciences' ROCE of 13.18% is a moderate figure. While it indicates profitability, it is crucial to examine its consistency over time. A sustained ROCE of this level helps in slowly building a competitive moat. We want to understand if this level of ROCE is enough to defend against rising costs and increased competition. We are looking for consistency and sustained performance in the long run.
Compared to peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, understanding Gufic Biosciences' specific product portfolio and geographic focus is vital. Analyzing the strength of their distribution network and ability to innovate will provide a more complete picture of its long-term prospects. A detailed look into the company's debt levels and cash flow generation will further inform our assessment of its financial health and ability to weather potential economic downturns. Our analysis is observational and focuses on objectively interpreting the available data.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Gufic Biosciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GUFICBIO across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (18.21%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (16.69% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (19.04% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (25.23% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (72.50%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 64.59x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-31.40%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Negative Free Cash Flow (₹-184.00 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 3.99%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Gufic Biosciences Ltd Financial Statements
Comprehensive financial data for Gufic Biosciences Ltd including income statement, balance sheet and cash flow
About GUFICBIO (Gufic Biosciences Ltd)
Gufic Biosciences Ltd (GUFICBIO) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹3.51K (Cr). Gufic Biosciences Ltd has delivered a Return on Equity (ROE) of 12.32% and a ROCE of 13.18%. The debt-to-equity ratio stands at 0.59, reflecting the company's capital structure. Investors tracking GUFICBIO share price can monitor key metrics including P/E ratio, promoter holding of 72.50%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
GUFICBIO Share Price: Frequently Asked Questions
What is the current share price of Gufic Biosciences Ltd (GUFICBIO)?
As of 19 Feb 2026, 06:18 am IST, Gufic Biosciences Ltd share price is ₹291.80. The GUFICBIO stock has a market capitalisation of ₹3.51K (Cr) on NSE/BSE.
Is GUFICBIO share price Overvalued or Undervalued?
GUFICBIO share price is currently trading at a P/E ratio of 64.59x, compared to the industry average of 31.77x. Based on this relative valuation, the Gufic Biosciences Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of GUFICBIO share price?
The 52-week high of GUFICBIO share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Gufic Biosciences Ltd share price?
Key factors influencing GUFICBIO share price include quarterly earnings growth (Sales Growth: 12.85%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Gufic Biosciences Ltd a good stock for long-term investment?
Gufic Biosciences Ltd shows a 5-year Profit Growth of 25.23% and an ROE of 12.32%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.59 before investing in GUFICBIO shares.
How does Gufic Biosciences Ltd compare with its industry peers?
Gufic Biosciences Ltd competes with major peers in the Pharmaceuticals. Investors should compare GUFICBIO share price P/E of 64.59x and ROE of 12.32% against the industry averages to determine competitive standing.
What is the P/E ratio of GUFICBIO and what does it mean?
GUFICBIO share price has a P/E ratio of 64.59x compared to the industry average of 31.77x. Investors pay ₹65 for every ₹1 of annual earnings.
How is GUFICBIO performing according to Bull Run's analysis?
GUFICBIO has a Bull Run fundamental score of 44.3/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does GUFICBIO belong to?
GUFICBIO operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Gufic Biosciences Ltd share price.
What is Return on Equity (ROE) and why is it important for GUFICBIO?
GUFICBIO has an ROE of 12.32%, which shows decent profitability but room for improvement. ROE measures how efficiently Gufic Biosciences Ltd generates profits from shareholders capital.
How is GUFICBIO debt-to-equity ratio and what does it indicate?
GUFICBIO has a debt-to-equity ratio of 0.59, which indicates moderate leverage that should be monitored.
What is GUFICBIO dividend yield and is it a good dividend stock?
GUFICBIO offers a dividend yield of 0.03%, meaning you receive ₹0.03 annual dividend for every ₹100 invested in Gufic Biosciences Ltd shares.
How has GUFICBIO share price grown over the past 5 years?
GUFICBIO has achieved 5-year growth rates of: Sales Growth 16.69%, Profit Growth 25.23%, and EPS Growth 19.04%.
What is the promoter holding in GUFICBIO and why does it matter?
Promoters hold 72.50% of GUFICBIO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Gufic Biosciences Ltd.
What is GUFICBIO market capitalisation category?
GUFICBIO has a market capitalisation of ₹3507 crores, placing it in the Small-cap category.
How volatile is GUFICBIO stock?
GUFICBIO has a beta of N/A. A beta > 1 suggests the Gufic Biosciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is GUFICBIO operating profit margin trend?
GUFICBIO has a 5-year average Operating Profit Margin (OPM) of 18.21%, indicating the company's operational efficiency.
How is GUFICBIO quarterly performance?
Recent quarterly performance shows Gufic Biosciences Ltd YoY Sales Growth of 12.85% and YoY Profit Growth of -31.40%.
What is the institutional holding pattern in GUFICBIO?
GUFICBIO has FII holding of 0.33% and DII holding of 3.66%. Significant institutional holding often suggests professional confidence in the Gufic Biosciences Ltd stock.